59 related articles for article (PubMed ID: 30660191)
1. Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective.
Mohan N; Chia YY; Goh GH; Ting E; Teo K; Yeo TT
BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29102970
[TBL] [Abstract][Full Text] [Related]
2. Invasive Giant Prolactinoma.
Alkhaibary A; Alharbi A; Khairy S
World Neurosurg; 2024 Jan; 181():21-22. PubMed ID: 37827431
[TBL] [Abstract][Full Text] [Related]
3. Syndrome of inappropriate antidiuretic hormone with recurrent giant cabergoline-resistant prolactinoma.
Kanzaki A; Kadoya M; Katayama S; Koyama H
BMJ Case Rep; 2023 Sep; 16(9):. PubMed ID: 37770242
[TBL] [Abstract][Full Text] [Related]
4. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study.
Almalki MH; Alsuraikh MA; Almalki E; Aziz F; Almazrouei R; AlDahmani KM; Alshahrani F; Alaqeel M; Mahzari M; Ekhzaimy A
Pituitary; 2024 Apr; 27(2):197-203. PubMed ID: 38345719
[TBL] [Abstract][Full Text] [Related]
5. Commentary: Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy.
Andereggen L; Christ E
Front Endocrinol (Lausanne); 2024; 15():1371468. PubMed ID: 38510701
[No Abstract] [Full Text] [Related]
6. Obstructive hydrocephalus, fifth nerve and hypothalamus involvement: acute presentation of a giant prolactinoma.
Alkatari S; Aljohani N
Clin Med Insights Case Rep; 2012; 5():115-8. PubMed ID: 22855635
[TBL] [Abstract][Full Text] [Related]
7. Medically responsive amyloidogenic giant sellar-parasellar prolactinoma.
Singh AK; Shilpi ; Kumari G; Tangri R
Surg Neurol Int; 2024; 15():129. PubMed ID: 38741982
[TBL] [Abstract][Full Text] [Related]
8. Between a rock and a hard place: the role of DA induced tumor fibrosis in prolactinoma management.
Mamelak AN
J Clin Endocrinol Metab; 2024 Feb; ():. PubMed ID: 38380908
[No Abstract] [Full Text] [Related]
9. Correction: Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review.
Zúñiga D; Stumpf MAM; Monteiro ALS; Glezer A
J Endocrinol Invest; 2024 May; 47(5):1313. PubMed ID: 38079105
[No Abstract] [Full Text] [Related]
10. The challenges in the management of giant prolactinoma in young man.
Komisarz-Calik M; Zieliński G; Hubalewska-Dydejczyk A; Gilis-Januszewska A
Pol Arch Intern Med; 2024 May; ():. PubMed ID: 38809213
[No Abstract] [Full Text] [Related]
11. Giant Clinically Non-Functioning Pituitary Adenoma Presenting as New Onset Generalized Tonic‒Clonic Seizures: A Case Report.
Weerasekara P; Chandraratne N; Perera SL
Int Med Case Rep J; 2024; 17():527-533. PubMed ID: 38799383
[TBL] [Abstract][Full Text] [Related]
12. Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma.
Dhanwal DK; Sharma AK
Pituitary; 2011 Dec; 14(4):384-7. PubMed ID: 19381817
[TBL] [Abstract][Full Text] [Related]
13. Atypical giant prolactinoma with frontal lobe manifestations.
Arshad MF; Arambewela M; Debono M
BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30181411
[No Abstract] [Full Text] [Related]
14. Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report.
Casulari LA; de Castro LF; Kessler IM; Mendonça JL; de Fátima Magalhães Gonzaga M
J Med Case Rep; 2019 Jun; 13(1):183. PubMed ID: 31202268
[TBL] [Abstract][Full Text] [Related]
15. Prolactinoma extension as a contributing factor in dopamine agonist-induced CSF rhinorrhea: a systematic review of the literature.
Milton CK; Lee BJ; Voronovich ZA; Conner AK; McKinney KA; El Rassi ET; Lim J; Glenn CA
Br J Neurosurg; 2023 Oct; 37(5):976-981. PubMed ID: 33783287
[TBL] [Abstract][Full Text] [Related]
16. Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report.
Koguchi M; Nakahara Y; Ebashi R; Ogata A; Shimokawa S; Masuoka J; Abe T
J Med Case Rep; 2019 Jan; 13(1):18. PubMed ID: 30660191
[TBL] [Abstract][Full Text] [Related]
17. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
